Several studies have investigated the relationship between MYBL2 expression and an immunosuppressive tumor microenvironment, using online or offline bioinformatic tools in pan-cancer analyses and have proposed that MYBL2 can affect the tumor immune microenvironment by influencing the immune infiltration levels and expression levels of CD4 + T cells, CD8 + T cells, cancer-associated fibroblasts, and immune checkpoint-associated cells [22]. The gene discussed is CD8A; the disease is cancer.